Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Gillessen, Silke; Bossi, Alberto; Davis, ID; Bono, Johann de; Fizazi, Karim; James, ND; Mottet, Nicolas; Shore, Neal D.; Small, Eric J.; Smith, M. R.; Sweeney, Christopher J.; Tombal, Bertrand; Antonarakis, ES; Aparicio, AM; Aj, Armstrong; Attard, Gerhardt; Beer, TM; Beltran, Himisha; Bjartell, Anders; Blanchard, Pierre; Briganti, Alberto; Bristow, Robert G.; Bulbul, Muhammad; Caffo, Orazio; Castellano, Daniel; Castro, Elena; Cheng, Hans H.; Chi, K.; Chowdhury, Simon; Clarke, Caroline S.; Clarke, Noel W.; Daugaard, Gedske; Santis, Maria De; Durán, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason A.; Ekeke, ON; Evans, CP; Fanti, Stefano; Feng, F.Y.; Fonteyne, Valérie; Fossati, Nicola; Frydenberg, Mark; George, Daniel J.; Gleave, Martin; Gravis, G.; Halabi, Susan; Heinrich, Daniel; Herrmann, Ken; Higano, Celestia S.; Hofman, MS; Horváth, L.; Hussain, Maha; Jereczek-Fossa, B.A.; Jones, Robert J.; Kanesvaran, Ravindran; Kellokumpu-Lehtinen, P-L; Khauli, RB; Klotz, Laurence; Kramer, Gero; Leibowitz, Raya; Logothetis, C.; Mahal, Brandon A.; Maluf, Fernando C.; Mateo, Joaquín; Matheson, David; Mehra, Niven; Merseburger, Axel S.; Morgans, AK; Morris, Margaret J.; Mrabti, Hind; Mukherji, Deborah; Murphy, Dominic; Murthy, Vedang; Nguyen, Paul; Oh, William K.; Ost, Piet; O'Sullivan, J.; Padhani, Anwar R.; Pezaro, CJ; DMC, Poon; Pritchard, CC; Rabah, DM; Rathkopf, Dana E.; Reiter, Robert C.; Rubin, Mark A.; Ryan, CJ; Saad, Fred; Sade, J. P.; Sartor, Oliver; Scher, H I; Sharifi, Nima; Skoneczna, Iwona; Soule, Howard R.; Spratt, DE; Srinivas, Sandy; Sternberg, C.; Steuber, Thomas; Suzuki, Hiroyoshi; Sydes, MR; Me, Taplin; Tilki, Derya; Türkeri, Levent; Turco, Fabio; Uemura, Hirotsugu; Ürün, Yüksel; Vale, CL; Oort, Inge M. van; Vapiwala, Neha; Walz, Jochen; Yamoah, Kosj; Ye, D; Yu, EY; Zapatero, A.; Zilli, Thomas; Omlin, Aurelius

doi:10.1016/j.ejca.2023.02.018

Cited by 63 publications

(26 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current guidelines from the American Urological Association (AUA) recommend abiraterone and enzalutamide as grade A treatments, and docetaxel as a grade B treatment for mCRPC ( 17 ). Similarly, the Apccc expert consensus endorses abiraterone and enzalutamide as primary treatments ( 18 ). These recommendations contrast with our results, prompting an exploration of potential reasons for these discrepancies.…”

Section: Discussionmentioning

confidence: 99%

Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review

Zhang,

Weng,

Zhu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aimed to evaluate the relative efficacy and safety of first-line treatment options for metastatic castration-resistant prostate cancer (mCRPC).MethodsWe systematically searched electronic databases, including PubMed and Web of Science, for studies published from their inception to April 3rd, 2023. Inclusion criteria were: 1) Completed Phase III or IV randomized controlled trials (RCTs) registered on ClinicalTrials.gov; 2) Patients with a confirmed diagnosis of mCRPC who had not previously received chemotherapy or novel endocrine therapies. We conducted a network meta-analysis using R software (version 3.4.0). Network graphs and risk of bias graphs were generated using Stata 14.0 and RevMan 5.4, respectively. The primary outcome was overall survival (OS), and the secondary outcome was the incidence of severe adverse events (SAEs).ResultsSeven RCTs encompassing 6,641 patients were included. The network meta-analysis revealed that both docetaxel+prednisone (DP) and cabazitaxel+prednisone (CP) significantly improved OS compared to abiraterone. Compared to placebo, DP showed comparable results to both cabazitaxel 20 mg/m^2+prednisone (C20P) and cabazitaxel 25 mg/m^2+prednisone (C25P) in terms of OS. For SAEs, both DP and C20P were superior to C25P, with no statistical difference between C20P and DP. The probability ranking plots indicated that C25P ranked highest for OS, while DP ranked highest for SAEs.ConclusionsBased on our network meta-analysis, we recommend cabazitaxel 20 mg/m^2+prednisone (C20P) as the primary choice for first-line management of mCRPC, followed by DP. Enzalutamide and abiraterone are suggested as subsequent options. Radium-223 may be considered for patients presenting with bone metastases.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023443943.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review

Zhang,

Weng,

Zhu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The prognosis and selection of treatment for patients with mHSPC according to the criteria from the LATITUDE trial (i.e., low vs. high risk) is less often used [27]. Moreover, recommendations on the optimal treatment of these patients are derived from the prognostic model that stratifies these patients into good (i.e., LV and metachronous disease), intermediate (i.e., LV and synchronous or HV and metachronous disease), and poor (i.e., HV and synchronous disease) prognostic group [28]. However, the extent to which these prognostic factors are predictive of the outcome of a particular mHSPC treatment (i.e., chemotherapy, ART, or their combination) is questionable.…”

Section: Discussionmentioning

confidence: 99%

Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study

Omrčen¹,

Eterović²,

Jozić³

et al. 2023

neo

View full text Add to dashboard Cite

Six cycles of docetaxel in addition to androgen deprivation therapy (ADT) are currently one of the treatment options for patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Since the outcomes in patients with highvolume (HV) disease remain modest, we aimed to identify patients for more intensified treatment. We report a cohort of 73 consecutive patients with de novo mHSPC treated with early docetaxel at the

show abstract

“…During the most recent Advanced Prostate Cancer Consensus Conference (APCCC), 77% of panelists recommended radical local treatment of the primary tumor and ADT plus one of the ARPIs for treating synchronous, low-volume HNPC ( 13 ). Eighty-nine percent of panelists recommended ADT and an ARPI (with 40% of them adding docetaxel) to treat synchronous, high-volume HNPC.…”

Section: The New Treatment Landscape Its Benefits and Consequencesmentioning

confidence: 99%

EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors

Grisay,

Turco,

Litiere

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use of these therapies introduces notable side effects, prompting a need to revisit intermittent treatment duration. The EORTC 2238 De-Escalate trial is a pragmatic trial seeking to reassess the role of intermittent therapy in patients undergoing maximal androgen blockade (MAB) for metastatic hormone naïve prostate cancer (mHNPC), i.e., the combination of ADT with an ARPI, with the aims of reducing side effects, enhancing Quality of Life (QoL) and optimizing resource usage, while maintaining oncological benefits.

show abstract

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

Cited by 63 publications

References 100 publications

Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review

Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review

Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study

EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors

Contact Info

Product

Resources

About